Day: May 12, 2025

ePoster presentation advances the preclinical evaluation of the importance of SERCA2a function to reduce arrythmias with istaroxime and a selective SERCA2a activator in the setting of ischemia and reperfusion WARRINGTON, Pa., May 12, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced istaroxime and a selective SERCA2a activator data furthering the demonstration of reduction in arrythmias in an animal study. The data is in a poster presentation at the European Society of Cardiology Heart Failure Conference. Windtree Therapeutics will present an e-poster at the ESC Heart Failure Congress on the impact...

ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Micro Labs has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants (Accord Healthcare Inc; Alkem Laboratories Ltd.; Aurobindo...

PITTSBURGH, May 12, 2025 (GLOBE NEWSWIRE) — Longevity Health Holdings, Inc. (NASDAQ: XAGE) (“Longevity” or the “Company”), a bio-aesthetics company focused on longevity and healthy aging, today announced that it has resolved to effect a reverse stock split of the Company’s common stock and has determined the ratio to be 1-for-30. The Company’s stockholders approved the reverse stock split and granted the Longevity board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split at the Company’s Special Meeting of Stockholders held on March 24, 2025. The reverse stock split became effective on May 12, 2025, at 9:00 a.m., Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market (“Nasdaq”)...

NORTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) — CPS Technologies Corporation (NASDAQ:CPSH) (“CPS” or the “Company”) today announced that, as it did last year, the Company will participate in the Sidoti Microcap Virtual Conference on May 21 and 22, 2025. A general presentation by management will be held at 9:15 a.m. Eastern on May 21, with one-on-one calls scheduled throughout the 21st and 22nd; institutional investors are encouraged to contact Sidoti directly or CPS investor relations with any questions or to confirm a time to speak with management. The general presentation will be webcast and will subsequently be made available on the Company’s website. To watch the webcast live, please use this link: https://sidoti.zoom.us/webinar/register/WN_nHcLGwkQTsSHrESm9hD7aQ About CPSCPS is a technology and manufacturing leader in producing...

GREENWICH, Conn., May 12, 2025 (GLOBE NEWSWIRE) — Gabelli Funds will host its 17th Annual Media & Entertainment Symposium at the Harvard Club in New York City on Thursday, June 5, 2025. The symposium will feature discussions with leading companies and organizations across the media ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals, as well as Sports Investing, Media & Telecom Regulatory, and Advertising Panels. Attendees will also have the opportunity to meet with management in a one-on-one setting. For those who cannot attend in person, the symposium will also be available via webcast. Investors should contact their relationship person for more information or click on the link below to register.Presenting Companies 1×1 Meetings OnlyAtlanta Braves Holdings, Inc. (NASDAQ:...

Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287).Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04).Significantly fewer patients in the belapectin treatment arms experienced worsening of liver stiffness as measured by FibroScan®, reinforcing the potential beneficial effect of belapectin in halting the progression of MASH cirrhosis.NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, presented a late-breaking oral presentation of the NAVIGATE study analysis at the EASL 2025 Congress, on May 10, 2025, in Amsterdam, Netherlands. The NAVIGATE study...

GREENWICH, Conn., May 12, 2025 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (NasdaqGS: OXLCG) announced today that it will hold a conference call to discuss its fourth fiscal quarter earnings on Monday, May 19, 2025 at 9:00 AM ET. The toll-free dial-in number is 1-833-470-1428, access code number 818188. There will be a recorded replay of the call available for 30 days after the call. If you are interested in hearing the recording, please dial 1-866-813-9403. The replay pass-code number is 138532. About Oxford Lane Capital Corp. Oxford Lane Capital Corp. is a publicly-traded registered closed-end management investment company principally investing in debt and equity tranches of collateralized loan obligation...

RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other treatments for ophthalmic disorders, today announced presentations related to its IRD gene therapy programs at these upcoming scientific conferences in May. Presentation Details American Society of Gene & Cell Therapy (ASGCT) 28th Annual MeetingTitle: Evaluation of MERTK gene therapy in RCS rats following a single bilateral subretinal injectionDate/ time: May 13, 2025, from 6:00 to 7:00 pm ETPresenter: Mayur Choudhary Ph.D., Principal Scientist, Opus GeneticsFormat: PosterLocation: Poster Hall I2, Ernest N. Morial Convention Center, New Orleans   HighlightsRetinitis pigmentosa...

FREMONT, Calif., May 12, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced the launch of the Enphase® IQ® Balcony Solar System in Belgium. Designed for plug-and-play installation, the new system empowers apartment dwellers and homeowners with limited roof space to generate their own clean energy from balconies, patios, and small outdoor areas. It’s also a simple and affordable solution for fully off-grid use cases, offering reliable daytime power for cabins, camping sites, mobile home setups, and more. The IQ Balcony Solar System includes Enphase IQ8HC™ Microinverters, IQ® Balcony Gateway, and other components. Enphase also recently launched the product in Germany. ...

BOCA RATON, FL, May 12, 2025 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) announced today the purchase of 172,670 Solana (“SOL”) at an average purchase price of $136.81 and valued at approximately $23.6 million. This marks the Company’s 10th Solana purchase under its digital asset treasury strategy and the largest purchase to date. Following the transaction, DeFi Development Corp. now holds a total of 595,988 SOL, valued at approximately $102.7 million, inclusive of staking rewards. Below is a summary of DeFi Dev Corp’s current SOL position and key per-share metrics as of May 12, 2025:Total SOL Held: 595,988 Total SOL Held (USD): approximately $102.7 million Total Shares Outstanding: 2,037,531 SOL per Share (“SPS”): 0.293 SPS (USD): $50.42As with all previously purchased tokens, the most recently...